leadf
logo-loader
viewAntibe Therapeutics Inc

Echelon rates Antibe Therapeutics as 'top pick' as investors eagerly await Phase II data from ATB-346 study

The research firm is maintaining a Speculative Buy rating and a price target of C$1.40 on the stock

Antibe Therapeutics Inc -
ATB-346 targets acute and chronic pain associated with osteoarthritis

Antibe Therapeutics Inc (CVE:ATE) is a ‘top pick’, according to Echelon Wealth Partners in a new research note hailing the firm’s lead pain management drug ATB-346.

Data from Antibe’s Phase 2 study of ATB-346 is expected to be released in the coming weeks, with the fully-enrolled trial randomizing its last patient in February 2020.

The research firm is maintaining a Speculative Buy rating and a price target of C$1.40 on the stock (current price: C$0.47).

READ: Antibe Therapeutics enrolls last patient in Phase 2B dose-ranging study of lead drug ATB-346

ATB-346 performed “exceedingly well” in an already-completed 246-patient Phase I/II gastro-duodenal ulceration rate trial, analysts Douglas Loe and Siew Ching Yeo wrote in a note.

At a once-daily dose level of 250-mg, ATB-346 generated much lower gastrointestinal (GI) ulceration rate or severity than control patients treated with naproxen at its indicated dose of 550-mg twice daily, according to the analysts. Only 2.5% of ATB-346-treated patients endured any GI ulcer formation while 42% of naproxen-treated patients did.

Phase II sees the drug’s efficacy tested at even lower doses. The trial is testing ATB-346’s pain-mitigating activity at three separate doses – 150-mg, 200-mg and 250-mg once-daily.

“Clearly the respective dosage strengths of ATB-346 versus naproxen were substantially different and so the soon-to-be-completed Phase II knee osteoarthritis pain trial will be hugely critical to our investment thesis for providing insights into the analgesic power of ATB-346 at a dose now known to confer minimal risk of GI ulceration,” Loe and Yeo wrote.

The analysts said that a “key value inflection point” is forthcoming with the release of Phase II data. Echelon’s valuation is still focused on ATB-346, though preclinical pipeline of hydrogen sulfide-releasing drugs has its own attractive prospects.

Toronto-based Antibe develops safer, non-addictive medicines for pain and inflammation. The company’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine.

In addition to ATB-346, the company’s second pipeline drug ATB-352, targets the need for a non-addictive analgesic for treating post-surgical pain. ATB-340, meanwhile, is a GI-safe derivative of aspirin.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Antibe Therapeutics Inc

Price: 0.355 CAD

TSX-V:ATE
Market: TSX-V
Market Cap: $136.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

on 08/12/2020

2 min read